The antiulcer activity of a hydro-ethanolic extract prepared from the stems of Kielmeyera coriacea Mart. (Guttiferae) was evaluated in rats employing the ethanol-acid, acute stress and Indomethacin models to induce experimental gastric ulcers. Treatment with K coriacea hydro-ethanolic extract provided significant antiulcer protection in the ethanol-acid and Indomethacin models, but not in the acute stress model. These results suggested that the K coriacea hydro-ethanolic extract increased resistance to necrotizing agents, providing a direct, protective effect on the gastric mucosa. A atividade antiulcerogênica do extrato hidroetanólico de caule de Kielmeyera coriacea Mart. (Guttiferae) foi avaliada em ratos por meio de três modelos experimentais: etanol-ácido, indometacina e estresse agudo. O índice ulcerativo observado após o tratamento com o extrato de Kielmeyera coriacea foi comparado com a droga de referência, cimetidina. O tratamento com o extrato mostrou significante atividade anti-ulcerogênica nos modelos de indução de lesões de mucosa gástrica produzidas por etanol-ácido e indometacina, mas não contra úlcera induzida pelo modelo de estresse agudo. Etanol-ácido e agentes antiinflamatórios, como a indometacina, são compostos que produzem úlcera de mucosa gástrica. Os resultados deste estudo sugerem uma atividade protetora de mucosa gástrica para o extrato de Kielmeyera coriace
The aim of the present study was to investigate the pharmacological properties of the crude lyophilized extract (EBPC) of Paullinia cupana seeds (guaraná) and the semi-purified extracts (EPA and EPB) after acute or chronic administration by the oral route in rats. Anxiolytic-like, antidepressant-like and motor stimulant effects were evaluated using the plus maze (PMT), forced swimming (FST) and open field (OFT) tests, respectively. Acute or chronic administration of EBPC (3.0, 30.0 or 60.0 mg/kg) did not alter the percentage of entries or the time spent in the open arm in the PMT. In the FST, chronic treatment with 30.0 mg EBPC/kg and 4.0 mg EPA/kg extract decreased the immobility time similarly to the antidepressant reference drug, imipramine (20.0 mg/kg). Locomotor activity in the OFT was not increased by these extracts. Caffeine (10.0 mg/kg) significantly reduced the immobility time in the FST, but increased locomotor activity in the OFT, indicating psychostimulant activity. The EPB extract did not induce any effect after acute or chronic treatment in the different models used. The present results suggest that the crude EBPC extract and EPA extract produced an antidepressant-like effect after long-term administration.
Kielmeyera coriacea Mart. (Clusiaceae), known as "Pau Santo", is used to treat several tropical diseases. The hydroethanolic extract (HE) of Kielmeyera coriacea stems and its semi-pure dichloromethane constituent (DCM) produced an anti-immobility effect in rats submitted to the forced swimming test (FST), suggesting a antidepressant-like profile. This study evaluated the effect of intra-median raphe nucleus (MRN) microinjection of 1,3,7-trihydroxy-2-(3-methylbut-2-enyl)-xanthone, present in large quantity in the HE from Kielmeyera coriacea stems, on immobility behaviour in the FST in rats. The effects of xanthone were compared with intra-MRN microinjections of Way100635 (5-HT1A antagonist) or (+) 8-OH-DPAT (5-HT1A agonist). Locomotor activity in the open-field test (OFT) was evaluated as a complementary measure. Xanthone (0.3ng) or Way100635 (2.5microg) reduced, whereas (+) 8-OH-DPAT (5.0microg) increased immobility time in the FST. Way100635 (2.5 or 5.0microg) completely reversed the effects of (+) 8-OHDPAT (5.0microg), and potentiated the anti-immobility effect of the ineffective dose of xanthone (0.2ng) in the FST. The association of effective doses of (+) 8-OH-DPAT (5.0microg) and xanthone (0.3ng) annulled the effect of each compound on immobility time. These results suggest that xanthone acts as an antagonist at 5-HT1A autoreceptors in MRN and increases serotonin (5-HT) availability in projection regions, proving to be a prototype drug that may be useful in mood isorders such as depression, or indeed be a beneficial adjunctive treatment improving the efficacy and/or accelerating the effects of antidepressant drugs in patients with major depression.
The β-adrenergic blocker and 5-HT(1A) receptor antagonist pindolol has been combined with selective serotonin reuptake inhibitors (SSRIs) in patients with depressive and anxiety disorders to shorten the onset of the clinical action and/or increase the proportion of responders. The results of a previous study have shown that pindolol potentiates the panicolytic effect of paroxetine in rats submitted to the elevated T-maze (ETM). Since reported evidence has implicated the 5-HT(1A) receptors of the dorsal periaqueductal gray matter (DPAG) in the panicolytic effect of antidepressants, rats treated with pindolol (5.0mg/kg, i.p.) and paroxetine (1.5mg/kg, i.p.) received a previous intra-DPAG injection of the selective 5-HT(1A) antagonist, WAY-100635 (0.4 μg) and were submitted to the ETM. Pretreatment with WAY-100635 reversed the increase in escape latency, a panicolytic effect, determined by the pindolol-paroxetine combination. These results implicate the 5-HT(1A) receptors of the DPAG in the panicolytic effect of the pindolol-paroxetine combination administered systemically. They also give further preclinical support for the use of this drug combination in the treatment of panic disorder.
the present results show that the combination of the ineffective doses of pindolol and paroxetine significantly increased escape latency, indicating a selective panicolytic effect. These findings give preclinical support for the use of this drug combination in the treatment of panic disorder (PD).
ABSTRACT. The aim of the present study was to investigate psychotropic properties of the crude lyophilized hydroethanolic extract (HE) from Kielmeyera coriacea stems after acute or chronic administration by oral route (gavage) in rats. Anxiolytic, antidepressive and psychomotor stimulant effects were evaluated using Plus-Maze (PMT), Forced Swimming (FST) and Open Field (OFT) test experimental models, respectively. Evaluation of the extract stems (60.0 mg/kg) revealed decreased immobility time in the forced swimming test (FST), without increasing locomotor activity in OFT, after chronic administration. This effect of the extract was compared with imipramine (20.0 mg/kg). Acute administration of 120.0 mg/kg of extract stems increased the open arm entries percentage in the PMT. According to the results, Kielmeyera coriacea stems extract is effective as anxiolytic as well as an anti-depressive-like drugs. RESUMO: Atividade farmacológica do extrato hidroetanólico liofilizado de caule de Kielmeyera coriacea em ratos. O objetivo deste estudo foi investigar as propriedades psicotrópicas do extrato hidroetanólico liofilizado obtido de caule de Kielmeyera coriacea após tratamento agudo ou crônico por via oral (gavagem) em ratos. As atividades ansiolítica, antidepressiva e estimulante de sistema nervoso central, foram avaliadas através da utilização dos testes do labirinto em cruz elevado (LCE), nado forçado (NF) e campo-aberto (TCA), respectivamente. A administração crônica de EH de caule de Kielmeyera coriacea (60.0 mg/kg) produziu redução no tempo de imobilidade no teste do NF, comparável a imipramina (20.0 mg/kg), sem aumentar a atividade locomotora no TCA. A dose de 120.0 mg/kg do mesmo extrato aumentou significativamente a percentagem de entradas nos braços abertos no teste do LCE após administração aguda. Estes resultados mostram que EH de caule de Kielmeyera coriacea apresenta perfil de composto ansiolítico e antidepressivo.Palavras-chave: Kielmeyera coriacea, depressão, campo-aberto, teste do nado forçado, labirinto em cruz.elevado.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.